00 32 (0) 43 66 43 00       adresseBE
CHU Tour 4 (B 36) Ave Hippocrate 15 | B-4000 Liège BELGIUM

  • Ban Ltpb

About us

The Laboratory of Pharmaceutical Technology and Biopharmacy (LTPB) belongs to the Department of Pharmacy of the University of Liege (Belgium). For more than XX years, LTPB has developed a strong expertise in Pharmaceutical Technology.

The LTPB was founded in 1972 by the Professor François Jaminet

Prof. Luc Delattre, his successor, pushed further these established bases bringing novel research axes, such as direct compression, coating and sustained release formulations, broadening the expertise of the LTPB and pursuing fruitfully its education and research missions.

Today, this heritage lies in the hands of Professor Brigitte Evrard. She developed her expertise in several research fields including the development of advanced formulations for API with poor aqueous solubility, development and optimization of new pharmaceutical production processes (HME, PAT, SC CO2,..), ….

Professor Brigitte Evrard is surrounded by a team of researchers composed of a permanent scientist, Dr. Géraldine Piel, two post-doctoral researchers, Dr. Martine Cao and Dr. Anna Lechanteur and a dozen of phD students. The team is also helped by two technicians and a secretary.

LTPB's main objective is to design new pharmaceutical systems for controlled drug delivery and administration of drugs.

LTPB is made up of researchers from different disciplines (pharmacists, chemists, biologists, biomedical sciences graduates), which allows it to consider not only the formulation but also the physicochemical characterization and biological evaluation of medicines. With its multidisciplinary approach, the LTPB has considerable assets to address different research themes around drug formulation.

Working together in synergy, the LTPB innovates and optimizes industrial processes for drug manufacturing. As part of its activities, the LTPB develops modified drug release systems (accelerated, delayed or sustained) such as coated or matrix tablets, spheroids, liposomes or microparticles, new dermatological topical forms and varied dosage forms as preparations for inhalation, vaginal use, parenteral administration…

Research and routine activities take place in a quality environment (Federal Agency for Medicines and Health Products agreement since 1997, GMP accreditation since 2014).

I invite you to discover our current efforts and achievements by looking through this website. Have a pleasant visit!